北京万东医疗科技股份有限公司独立董事 关于第九届董事会第十一次会议相关事项的独立意见 根据《公司法》、《关于在上市公司建立独立董事制度的指导意见》、《上 市公司治理准则》和《公司章程》等相关规章制度的有关规定，作为北京 万东医疗科技股份有限公司（以下简称"公司"）独立董事，我们对公司 2023 年半年度募集资金存放与实际使用情况的专项报告发表如下意见： 公司关于2023年半年度募集资金存放与实际使用情况的专项报告，真 实、客观地反映了公司2023年1-6月募集资金的存放与实际使用情况，募集 资金存放与使用不存在违规行为，符合有关法律法规及《上海证券交易所 上市公司自律监管指引第1号——规范运作》、《公司章程》等相关法律法规 和公司制度的规定，切实保护了投资者的利益。因此，我们一致同意公司 募集资金存放与实际使用情况的专项报告。 北京万东医疗科技股份有限公司 邹卓 独立董事 李红霞 独立董事 (本页无正文,为《北京万东医疗科技股份有限公司独立董事关于第九届 董事会第十一次会议相关事项的独立意见》的签字页) 独立董事签字: 潘飞 独立董事 2023 年 8 月 28 日 ...

证券代码：600055 证券简称：万东医疗 编号：临 2023-020 北京万东医疗科技股份有限公司 第九届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京万东医疗科技股份有限公司第九届监事会第十一次会议于 2023 年 8 月 28 日以通讯表决方式召开。本次会议的会议通知及相关资料于 2023 年 8 月 22 日以电子邮件的方式向全体监事发出。会议应到 3 人，实到 3 人。本次 会议的召开符合《公司法》和《公司章程》的有关规定。会议形成如下决议： 监事会 一、 审议通过《公司 2023 年半年度报告及摘要》。 公司监事会根据《证券法》及其他法律法规的相关要求，对董事会编制 的 2023 年半年度报告进行了严格审核，认为： 1、公司 2023 年半年度报告的编制和审议程序符合法律法规、公司章程 和公司内部管理制度的各项规定； 2、公司 2023 年半年度报告的内容和格式符合中国证监会和上海证券交 易所的各项规定，该报告真实地反映出公司 2023 年半年度的经营管理和财务 状况等事项； 3、 ...

证券代码：600055 证券简称：万东医疗 编号：临 2023-019 北京万东医疗科技股份有限公司 第九届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 北京万东医疗科技股份有限公司第九届董事会第十一次会议以通讯表 决方式于 2023 年 8 月 28 日召开。本次会议的会议通知及相关资料于 2023 年 8 月 22 日以电子邮件的方式向全体董事发出。会议应到董事 9 人，实到 9 人，公司监事及高管人员出席、列席会议。本次会议的召开符合《公司法》 和《公司章程》的规定，所作决议合法有效。 会议由胡自强董事长主持，形成如下决议： 一、 审议通过《公司 2023 年半年度报告及摘要》。 具体内容详见上海证券交易所网站。 本议案表决结果：同意 9 票，反对 0 票，弃权 0 票。 二、 审议通过《关于公司 2023 年半年度募集资金存放与实际使用情 况的专项报告》。 具体内容详见公司披露于上海证券交易所网站的（临 2023-021）《万东 医疗关于公司 2023 年半年度募集资金存放与实际使用情况 ...

证券代码：600055 证券简称：万东医疗 编号：临 2023-022 北京万东医疗科技股份有限公司关于 使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 重要内容提示： 产品种类：银行理财 本次现金管理总额：1.5 亿元 履行的审议程序：2023 年4 月17 日召开的第九届董事会第九次会议、 第九届监事会第九次会议及 2023 年 5 月 12 日召开的 2022 年年度股东大会 审议批准《关于使用部分暂时闲置募集资金进行现金管理的议案》。 一、情况概述 （一）现金管理目的 北京万东医疗科技股份有限公司（以下简称"公司"）为提高募集资 金效率，合理利用部分闲置募集资金，在确保不影响募集资金项目建设和 使用、募集资金安全的情况下，增加公司的收益，为公司及股东获取更多 回报。 （二）现金管理金额 本次现金管理总金额为 1.5 亿元。 （三）资金来源及相关情况 本次现金管理的资金来源为闲置募集资金。 经中国证券监督管理委员会《关于核准北京万东医疗科技股份有限公 司非公开发行股票的批复》 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥255,084,691.08, representing a year-on-year increase of 21.12%[6] - The net profit attributable to shareholders for Q1 2023 was ¥30,438,016.42, reflecting a year-on-year growth of 23.57%[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥29,282,857.58, up 24.34% year-on-year[6] - Total revenue for Q1 2023 reached ¥255,084,691.08, a 21.1% increase from ¥210,601,112.63 in Q1 2022[24] - Operating profit for Q1 2023 was ¥35,458,280.90, compared to ¥30,482,372.71 in Q1 2022, reflecting an increase of 16.4%[27] - Net profit for Q1 2023 amounted to ¥29,673,219.40, up from ¥25,382,468.15 in Q1 2022, representing a growth of 16.5%[29] - The company reported a total comprehensive income of ¥29,673,219.40 for Q1 2023, compared to ¥25,382,468.15 in Q1 2022, reflecting an increase of 16.5%[29] Cash Flow - The net cash flow from operating activities was -¥44,623,764.36, a decrease of 74.35% compared to the same period last year[6] - Cash flow from operating activities showed a net outflow of ¥44,623,764.36 in Q1 2023, worsening from a net outflow of ¥25,595,019.71 in Q1 2022[31] - Net cash flow from investing activities was -$153,040,931.44, compared to $128,582,285.46 in the previous period[32] - Total cash inflow from financing activities reached $2,090,259,364.94, while cash outflow was $636,779.93, resulting in a net cash flow of $2,053,539,364.94[32] - The ending cash and cash equivalents balance was $3,033,170,415.68, down from $3,231,471,891.41 at the beginning of the period[32] - Cash inflow from investment activities totaled $50,831,601.16, significantly lower than $162,717,036.16 in the previous period[32] - Cash outflow for capital expenditures was $3,872,532.60, compared to $1,134,750.70 in the previous period[32] - The company received $50,000,000.00 from investment recoveries, down from $155,500,000.00 previously[32] - The company reported a significant increase in cash inflow from financing activities, primarily due to new investments received[32] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to ¥5,270,779,752.96, showing a slight increase of 0.16% from the end of the previous year[9] - The equity attributable to shareholders at the end of Q1 2023 was ¥4,635,842,013.21, which is a 0.66% increase from the previous year-end[9] - The total current assets were CNY 4,273,359,853.97, showing a marginal increase from CNY 4,266,343,912.23[20] - The total current liabilities decreased to CNY 470,583,949.12 from CNY 492,076,591.29, a reduction of about 4.4%[22] - The non-current assets totaled CNY 997,419,898.99, slightly up from CNY 996,255,263.50[22] - The total liabilities were CNY 486,248,381.68, down from CNY 507,740,023.85, indicating a decrease of approximately 4.2%[22] - Total liabilities as of Q1 2023 were ¥530,488,831.82, a decrease from ¥551,981,473.99 in the previous year[24] - Total equity attributable to shareholders reached ¥4,635,842,013.21 in Q1 2023, up from ¥4,605,403,996.79 in Q1 2022[24] Earnings and Expenses - The company's basic earnings per share for Q1 2023 was ¥0.043, down 6.52% year-on-year[6] - The weighted average return on equity for Q1 2023 was 0.66%, a decrease of 0.36% compared to the same period last year[6] - Research and development expenses increased to ¥28,849,435.87 in Q1 2023, compared to ¥24,860,818.21 in Q1 2022, marking a rise of 15.9%[27] - Sales expenses rose to ¥47,730,558.94 in Q1 2023, up from ¥39,339,624.00 in Q1 2022, indicating a 21.5% increase[27] Financial Assets - The increase in trading financial assets by 149.50% was due to the use of temporarily idle funds to purchase financial products[12] - The company reported a decrease in cash flow from investing activities by 219.02% due to the purchase of financial products with temporarily idle funds[12] - The company reported a significant increase in financial assets, with trading financial assets rising to CNY 250,422,580.82 from CNY 100,369,008.22, a growth of about 149.5%[20] Related Party Transactions - The company has not disclosed any related party relationships among the top shareholders, indicating no known concerted actions as per the regulations[18]

Financial Performance - The company's total revenue for 2022 was CNY 1,121,203,548.49, a decrease of 3.02% compared to CNY 1,156,174,686.02 in 2021[32] - The net profit attributable to shareholders for 2022 was CNY 175,369,143.35, down 4.27% from CNY 183,193,054.55 in the previous year[32] - Basic earnings per share for 2022 were CNY 0.266, a decrease of 22.22% from CNY 0.342 in 2021[32] - The weighted average return on net assets for 2022 was 4.37%, down from 7.81% in 2021, reflecting a decrease of 3.44 percentage points[32] - The total profit for the year was 192 million RMB, down 7.14% year-on-year, while the net profit attributable to shareholders was 175 million RMB, a decline of 4.27%[92] - The company's cash flow from operating activities increased significantly by 106.64% to 185 million RMB compared to the previous year[92] Market Position and Sales - The company maintains a leading position in DR, DRF, and mobile DR products, while being in the second tier for DSA, superconducting MRI, and CT in the domestic market[49] - The company holds a leading position in the domestic market for DR and DRF products, with a market share of 19.6% in conventional DR sales, ranking first in the industry[68] - The mobile DR product line accounted for 10.76% of the market share, ranking third in the industry, with the domestic market dominated by local brands holding over 80%[81] - The company’s CT sales have entered the top ten in the domestic market, with nearly 100 units sold in 2022, and plans to enhance its product line with the upcoming launch of 64-slice CTs in 2023[63] - The company experienced a 30% year-over-year decrease in DR product sales due to a significant reduction in public bidding quantities, while CT product sales increased by 300% driven by the demand for economical 16-slice and newly launched 32-slice CTs[55] Research and Development - The company expanded its R&D team from 170 to 212 personnel during the reporting period, with R&D staff now accounting for 23% of the total workforce[38] - Research and development expenses increased to CNY 137.76 million, representing a growth of 23.57% year-on-year, with R&D expenses accounting for 12.29% of total revenue[111][105] - The company is focusing on developing high-end medical imaging equipment, including MRI systems, X-ray machines, and CT scanners[120] - The company has obtained 8 patents, including breakthroughs in advanced clinical applications for its 1.5T superconducting MRI, which will support product sales[78] Product Development and Innovation - The company launched its first 1.5T helium-free superconducting MRI, completing the series layout for 1.5T superconducting MRI products, which is expected to address the reliance on imported helium[108] - The company is developing new economic and hybrid DSA products to enhance its competitiveness in a market where over 90% is currently dominated by imported brands[89] - The company is actively developing new DSA products to meet the growing market demand, focusing on cost-effective solutions using domestic core components[72] - The company plans to enhance market promotion for new products including full-field DR, 1.5T helium-free superconducting MRI, and 32-slice CT, with several DR models expected to launch in the first half of 2023[197] Market Trends and Opportunities - The domestic medical imaging equipment market is projected to reach RMB 275 billion for CT devices and RMB 264 billion for MRI devices by 2030, indicating strong growth potential[49] - The aging population is driving an increased demand for medical resources, leading to a greater need for medical equipment configuration[56] - The government’s financial support policies, including interest-subsidized loans, are expected to stimulate medical equipment procurement, benefiting various equipment manufacturers[52] - The domestic market for digital gastrointestinal machines is projected to have an annual installation increase of around 800 units, with the company achieving approximately 200 units sold in 2022, capturing about 20% of the market[75] Strategic Initiatives - The company plans to implement a differentiated competition strategy by developing new products such as CBCT-DR and digital mammography machines to increase average sales price and gross margin[193] - The company is actively participating in international medical device exhibitions and establishing R&D centers abroad to enhance its export capabilities[53] - The company is focusing on expanding its market share in the CT segment, with a strategic emphasis on both high-end and low-end products to meet diverse hospital needs[63] - The company is implementing a fill-and-bridge strategy to enhance its competitiveness in the 64-slice and above CT market, which is currently dominated by imported brands[194] Risk Management and Compliance - The company has identified potential risks in its annual report, urging investors to pay attention to future developments[2] - The company is implementing a risk management approach in clinical trials, emphasizing the responsibilities of sponsors and researchers[170] - The company is streamlining registration processes and reducing approval times for medical devices, enhancing operational efficiency[168]

证券代码：600055 证券简称：万东医疗 编号：临 2023-002 北京万东医疗科技股份有限公司 关于召开2022年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 责任。 重要内容提示: 会议召开时间：2023 年 04 月 21 日(星期五) 下午 15:00-16:00 会议召开地点： 上海证券 交易所上证路演中心（ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 14 日(星期五) 至 04 月 20 日(星期四) 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wdm_ir@wandong.com.cn 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、参加人员 公司总裁谢宇峰先生，董事会秘书任志林先生，副总裁、财务负责人井 晓权先生，独立董事邹卓先生。 四、投资者参加方式 北京 ...

2022 年第三季度报告 单位：元 币种：人民币 证券代码：600055 证券简称：万东医疗 北京万东医疗科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 主要会计数据和财务指标 本报告期比 年初至报告 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|---------------------------|----------------|----------------------------------| | ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 456,521,773.90, a decrease of 7.74% compared to CNY 494,828,800.79 in the same period last year[22]. - The net profit attributable to shareholders for the first half of 2022 was CNY 59,311,322.24, down 28.72% from CNY 83,210,335.63 in the previous year[22]. - Basic earnings per share for the first half of 2022 were CNY 0.096, a decrease of 37.66% compared to CNY 0.154 in the same period last year[22]. - The weighted average return on net assets decreased by 1.86 percentage points to 1.72% from 3.58% in the previous year[22]. - The company achieved a revenue of 457 million yuan, a year-on-year decrease of 7.74%, and a net profit attributable to shareholders of 59.31 million yuan, down 28.72% year-on-year[44]. - The decline in revenue was primarily due to a significant drop in the domestic DR and mobile DR markets, while sales of superconducting MRI, DSA, and CT products increased, offsetting some losses[44]. - The company reported a net profit of -1 million yuan, currently in liquidation[60]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to CNY 20,878,247.01, compared to a negative cash flow of CNY -15,726,862.93 in the same period last year, representing a 232.76% increase[22]. - The total assets of the company reached CNY 5,011,784,728.52, an increase of 74.26% from CNY 2,875,979,734.33 at the end of the previous year[22]. - The total monetary funds at the end of the reporting period reached ¥2,667,864,774.29, representing 53.23% of total assets, a significant increase of 201.15% from the previous year[54]. - The company's inventory increased by 25.51% to ¥241,348,931.90, compared to ¥192,294,398.21 in the previous year[54]. - The total current assets amount to 3,949,205,293.10 RMB, compared to 1,860,951,916.77 RMB at the beginning of the period[109]. - Cash and cash equivalents are reported at 2,667,864,774.29 RMB, up from 885,879,669.88 RMB at the beginning of the period[109]. Research and Development - Research and development expenses increased by 29.26% to ¥49,342,221.63, reflecting the company's commitment to enhancing R&D efforts[49]. - The company is actively developing new products based on market demand, ensuring a customer-centric approach in its operations[28]. - The company plans to accelerate the development of differentiated products for high-level hospitals, including long-field DR and new mobile DR models[45]. Market and Product Development - The company specializes in the research, manufacturing, and sales of imaging medical devices, including X-ray machines, DSA systems, MRI systems, and X-CT systems, positioning itself as a leading player in the domestic medical device industry[28]. - The demand for 1.5T superconducting MRI systems is expected to grow, driven by breakthroughs in key technologies and increasing comfort for patients, making it a focus for hospital procurement[32]. - The DSA product procurement is accelerating in secondary hospitals due to policy support for domestic medical equipment, narrowing the performance gap with imported brands[33]. - The overall CT market grew by 4% year-on-year, with the company experiencing significant sales growth in this segment despite supply chain pressures[45]. Shareholder and Corporate Governance - The company did not distribute profits or increase capital reserves during the mid-year period[7]. - The company completed a non-public offering of shares during the reporting period, and the financial data reflects the latest number of shares[22]. - The company completed the non-trading transfer of 4,938,333 shares to the employee stock ownership plan on June 13, 2022[66]. - The company will continue to exercise shareholder rights in accordance with laws and regulations, ensuring the independence of Wandong Medical in assets, personnel, finance, business, and organization[75]. Related Party Transactions - The company reported related party transactions amounting to ¥2,055,685.80 for purchasing raw materials from Hangzhou Wandong Electronics, accounting for 0.94% of similar transactions[84]. - The company also reported related party transactions of ¥3,779,255.60 for purchasing products and services from Jiangsu Yuyue Medical Equipment, representing 1.73% of similar transactions[84]. - The total revenue from related party transactions amounted to CNY 59,235,194.01, representing a 17.52% increase[87]. Financial Reporting and Compliance - The financial report has been approved by the board of directors on August 26, 2022[162]. - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position and operating results accurately[169]. - The company has implemented specific accounting policies and estimates tailored to its operational characteristics[168].